<code id='045559DA61'></code><style id='045559DA61'></style>
    • <acronym id='045559DA61'></acronym>
      <center id='045559DA61'><center id='045559DA61'><tfoot id='045559DA61'></tfoot></center><abbr id='045559DA61'><dir id='045559DA61'><tfoot id='045559DA61'></tfoot><noframes id='045559DA61'>

    • <optgroup id='045559DA61'><strike id='045559DA61'><sup id='045559DA61'></sup></strike><code id='045559DA61'></code></optgroup>
        1. <b id='045559DA61'><label id='045559DA61'><select id='045559DA61'><dt id='045559DA61'><span id='045559DA61'></span></dt></select></label></b><u id='045559DA61'></u>
          <i id='045559DA61'><strike id='045559DA61'><tt id='045559DA61'><pre id='045559DA61'></pre></tt></strike></i>

          knowledge

          knowledge

          author:explore    Page View:78827
          Adobe

          Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

          The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

          advertisement

          Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Brain technologies pose threats that are all too real, experts warn
          Brain technologies pose threats that are all too real, experts warn

          Inthe2011film"Limitless,"mysterypillsletBradleyCooper'sstrugglingwriteraccess100percentofhisbrain,ma

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          Class action alleges UnitedHealth concealed DOJ probe

          AdobeYou’rereadingthewebversionofHealthCareInc.,STAT’sweeklynewsletterfollowingtheflowofmoneyinmedic